title: Luciferase reporter gene assay on human, murine and rat histamine H4 receptor orthologs: correlations and discrepancies between distal and proximal readouts.
abstract: The investigation of the (patho)physiological role of the histamine H4 receptor (H4R) and its validation as a possible drug target in translational animal models are compromised by distinct species-dependent discrepancies regarding potencies and receptor subtype selectivities of the pharmacological tools. Such differences were extremely pronounced in case of proximal readouts, e. g. [(32)P]GTPase or [(35)S]GTPγS binding assays. To improve the predictability of in vitro investigations, the aim of this study was to establish a reporter gene assay for human, murine and rat H4Rs, using bioluminescence as a more distal readout. For this purpose a cAMP responsive element (CRE) controlled luciferase reporter gene assay was established in HEK293T cells, stably expressing the human (h), the mouse (m) or the rat (r) H4R. The potencies and efficacies of 23 selected ligands (agonists, inverse agonists and antagonists) were determined and compared with the results obtained from proximal readouts. The potencies of the examined ligands at the human H4R were consistent with reported data from [(32)P]GTPase or [(35)S]GTPγS binding assays, despite a tendency toward increased intrinsic efficacies of partial agonists. The differences in potencies of individual agonists at the three H4R orthologs were generally less pronounced compared to more proximal readouts. In conclusion, the established reporter gene assay is highly sensitive and reliable. Regarding discrepancies compared to data from functional assays such as [(32)P]GTPase and [(35)S]GTPγS binding, the readout may reflect multifactorial causes downstream from G-protein activation, e.g. activation/amplification of or cross-talk between different signaling pathways.
authors.affiliation: Institute of Pharmacy, University of Regensburg, Regensburg, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Nordemann
authors.forename: David
authors.initials: D
authors.lastname: Wifling
authors.forename: David
authors.initials: D
authors.lastname: Schnell
authors.forename: Günther
authors.initials: G
authors.lastname: Bernhardt
authors.forename: Holger
authors.initials: H
authors.lastname: Stark
authors.forename: Roland
authors.initials: R
authors.lastname: Seifert
authors.forename: Armin
authors.initials: A
authors.lastname: Buschauer
mesh_terms: D000818:Animals; D054314:Drug Inverse Agonism; D017930:Genes, Reporter / Q000235:genetics*; D005821:Genetic Techniques; D057809:HEK293 Cells; D006801:Humans; D008024:Ligands; D008156:Luciferases / Q000235:genetics*; D051379:Mice; D051381:Rats; D043562:Receptors, G-Protein-Coupled / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism*; D011968:Receptors, Histamine / Q000235:genetics* / Q000378:metabolism*; D000074040:Receptors, Histamine H4; D012689:Sequence Homology, Nucleic Acid
chemical_list: C418607:HRH4 protein, human; D008024:Ligands; D043562:Receptors, G-Protein-Coupled; D011968:Receptors, Histamine; D000074040:Receptors, Histamine H4; D008156:Luciferases
references.citation: J Med Chem. 2003 Dec 4;46(25):5445-57
references.pmid: 14640553
references.citation: Mol Pharmacol. 2001 Mar;59(3):427-33
references.pmid: 11179435
references.citation: Biochem Pharmacol. 2012 Jul 15;84(2):192-203
references.pmid: 22516788
references.citation: J Med Chem. 2009 Oct 22;52(20):6297-313
references.pmid: 19791743
references.citation: J Med Chem. 2006 Nov 16;49(23):6650-1
references.pmid: 17154494
references.citation: J Biomol Screen. 2002 Apr;7(2):141-8
references.pmid: 12006113
references.citation: J Med Chem. 2008 Nov 27;51(22):7094-8
references.pmid: 18983139
references.citation: J Immunol. 2006 Jun 1;176(11):7062-70
references.pmid: 16709868
references.citation: Mol Pharmacol. 2011 Apr;79(4):749-57
references.pmid: 21134907
references.citation: Br J Pharmacol. 2009 May;157(1):14-23
references.pmid: 19413568
references.citation: J Biol Chem. 1995 Nov 24;270(47):28268-75
references.pmid: 7499324
references.citation: Trends Pharmacol Sci. 2013 Jan;34(1):13-32
references.pmid: 23228711
references.citation: Mol Pharmacol. 2001 Mar;59(3):420-6
references.pmid: 11179434
references.citation: J Immunol. 2007 Jun 15;178(12):8081-9
references.pmid: 17548646
references.citation: Curr Opin Pharmacol. 2001 Oct;1(5):526-32
references.pmid: 11764780
references.citation: J Pharmacol Exp Ther. 2003 Jun;305(3):1212-21
references.pmid: 12626656
references.citation: Br J Pharmacol. 2003 Apr;138(7):1340-50
references.pmid: 12711635
references.citation: Br J Pharmacol. 2000 Jul;130(5):1021-30
references.pmid: 10882386
references.citation: Biochemistry. 2009 Feb 17;48(6):1424-38
references.pmid: 19166345
references.citation: Exp Dermatol. 2009 Jan;18(1):57-63
references.pmid: 18647342
references.citation: Trends Pharmacol Sci. 2011 Apr;32(4):250-7
references.pmid: 21414671
references.citation: Biochemistry. 2009 Apr 21;48(15):3387-97
references.pmid: 19243146
references.citation: Trends Pharmacol Sci. 2005 Sep;26(9):462-9
references.pmid: 16054239
references.citation: Mol Pharmacol. 2001 Mar;59(3):434-41
references.pmid: 11179436
references.citation: Br J Pharmacol. 2009 May;157(1):44-54
references.pmid: 19413570
references.citation: J Med Chem. 2008 Oct 23;51(20):6547-57
references.pmid: 18817367
references.citation: Mol Pharmacol. 2009 Nov;76(5):1019-30
references.pmid: 19720730
references.citation: J Biol Chem. 1998 Apr 10;273(15):8727-40
references.pmid: 9535850
references.citation: PLoS One. 2012;7(1):e30285
references.pmid: 22272324
references.citation: Pharmacol Ther. 2007 Mar;113(3):594-606
references.pmid: 17275092
references.citation: Bioorg Med Chem. 2009 Oct 15;17(20):7186-96
references.pmid: 19773175
references.citation: Mol Pharmacol. 2012 Dec;82(6):1174-82
references.pmid: 22973061
references.citation: J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21
references.pmid: 15947036
references.citation: J Biol Chem. 2000 Nov 24;275(47):36781-6
references.pmid: 10973974
references.citation: J Biol Chem. 1999 Dec 10;274(50):35539-45
references.pmid: 10585428
references.citation: J Med Chem. 2009 Apr 23;52(8):2623-7
references.pmid: 19317445
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):301-17
references.pmid: 21800093
references.citation: J Biol Chem. 1998 Apr 10;273(15):9297-305
references.pmid: 9535924
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2012 Feb;385(2):145-70
references.pmid: 22033803
references.citation: Drug Discov Today. 2009 Oct;14(19-20):982-91
references.pmid: 19638320
references.citation: Nat Rev Drug Discov. 2004 Feb;3(2):125-35
references.pmid: 15040577
references.citation: Mol Pharmacol. 2011 Apr;79(4):631-8
references.pmid: 21266488
references.citation: J Pharmacol Exp Ther. 2001 Mar;296(3):1058-66
references.pmid: 11181941
references.citation: J Pharmacol Exp Ther. 2004 Apr;309(1):404-13
references.pmid: 14722321
references.citation: Nat Rev Drug Discov. 2008 Jan;7(1):41-53
references.pmid: 18172439
references.citation: Methods Mol Biol. 2009;552:319-28
references.pmid: 19513660
references.citation: Eur J Pharmacol. 2007 Jun 1;563(1-3):240-4
references.pmid: 17382315
references.citation: J Pharmacol Exp Ther. 2001 Oct;299(1):121-30
references.pmid: 11561071
references.citation: Pharmacology. 2010;85(4):217-23
references.pmid: 20215812
references.citation: J Biol Chem. 2000 Dec 29;275(52):41447-57
references.pmid: 11006286
references.citation: Mol Pharmacol. 2010 May;77(5):734-43
references.pmid: 20103609
references.citation: Inflamm Res. 2009 Jun;58(6):285-91
references.pmid: 19184344
references.citation: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references.pmid: 4202581
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2011 May;383(5):457-70
references.pmid: 21359967
references.citation: Br J Pharmacol Chemother. 1959 Mar;14(1):48-58
references.pmid: 13651579